We cordially invite you to participate in the inaugural Pan Pacific Leukemia Conference, an exciting new chapter in leukemia treatment and research. Building on the success of the prestigious Pan Pacific Lymphoma Conference (PPLC), this conference aims to convene a diverse assembly of leading clinicians and researchers to share groundbreaking insights and foster interdisciplinary collaboration.
This gathering will delve into cutting-edge developments in leukemia research, explore innovative therapeutic modalities, and discuss the latest advancements in patient care. Attendees will have the unique opportunity to engage with fellow scholars and practitioners, contributing to the ongoing discourse shaping the future of leukemia treatment.
As part of the activity, the conference will feature "Meet the Expert" sessions, offering community oncologists the chance to engage directly with specialists. These interactive discussions will focus on the clinical challenges surrounding myeloproliferative neoplasms, myelodysplastic syndromes, and both acute and chronic leukemias.
This landmark event, hosted by the University of Nebraska Medical Center in collaboration with The University of Texas MD Anderson Cancer Center, is intended for oncologists, hematologists, pathologists, clinical scientists, advanced practice providers, nurses, and pharmacists.
We encourage you to take this opportunity to connect, collaborate, and contribute to the advancement of leukemia care. Join us as we collectively push the boundaries of knowledge and improve outcomes for patients!
Date: July 15-18, 2025
Location: Hyatt Regency Maui Resort and Spa — 200 Nohea Kai Dr, Lahaina, HI 96761
At the conclusion of the conference, the participants should be better able to:
Discuss pathological and molecular advances in acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia and clonal hematopoiesis, and their incorporation into clinical practice.
Learn about newer therapeutic strategies in acute leukemias, chronic leukemias, myelodysplastic syndrome, and myeloproliferative disorders.
Describe advances in Chimeric Antigen Receptor (CAR) T-cell therapy for acute lymphocytic leukemia.
Describe the emerging role of doublets and triplets combination targeted therapies in CLL.
Describe the role of upfront allogeneic stem cell transplantation in acute leukemias and myelodysplastic syndrome.
Identify the importance of supportive care in the management of acute leukemias, myeloid malignancies, and allogeneic stem cell transplantation.